Join to view full profile
3400 Civic Center Boulevard12-114 SouthPhiladelphia, PA 19104
Phone+1 215-662-3929
Fax+1 215-573-2652
Dr. Vonderheide is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1996 - 1998
Mass General Brigham/Massachusetts General HospitalResidency, Internal Medicine, 1993 - 1996
Harvard Medical SchoolClass of 1993
Certifications & Licensure
PA State Medical License 2001 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2007
Clinical Trials
- Tremelimumab and CP-870,893 in Patients With Metastatic Melanoma
- Phase 1 Study of Preoperative Gemcitabine Plus CP-870, 893 Followed by Addition of CP-870,893 to Standard -Of-care Adjuvant Chemoradiation for Patients With Newly Diagnosed Resectable Pancreatic Carcinoma
- Redosing With CP-870, 893 in Patients With Clinical Benefit After a Single Infusion From A Phase I, Open-Label, Dose-Escalation Study of CP-870,893 in Patients With Solid Tumors
Publications & Presentations
PubMed
- Deep learning representations of human Immune Health for precision immunology.Matthew E Lee, Jaesik Kim, Matei Ionita, Michelle L McKeague, Jonghyun Lee
Biorxiv. 2026-07-20 - Feasibility and Acceptability of Automated Texts to Offer, Screen, and Enroll Patients in a Cancer Clinical Trial Financial Reimbursement Program: Mixed Methods Study.Ashley E Santaniello, Hena Patel, Sarah Milinski, Mohan Balachandran, Vivian Nguyen
JMIR Formative Research. 2026-07-09 - Long-Term Outcomes of Patients With BRCA+ or PALB2+ Pancreatic Cancer Treated With Maintenance Rucaparib: A Secondary Analysis of a Nonrandomized Clinical Trial.Kim A Reiss, Mingyi Xia, Mwangala Akamandisa, Kurt D'Andrea, Brad Wubbenhorst
JAMA Oncology. 2026-06-01
Journal Articles
- Unique Pattern of Neutrophil Migration and Function During Tumor ProgressionNeil Hockstein, Charles Mulligan, Robert H Vonderheide, Gregory Masters, Nature
- Radiotherapy and CD40 Activation Separately Augment Immunity to Checkpoint Blockade in CancerAndrew J Rech, Robert H Vonderheide, Jonathan J Kotzin, Clinical Cancer Research
Press Mentions
Leonard Abramson, Health Care Innovator and Philanthropist, Dies at 93July 14th, 2026- ‘The Most Significant Change in 20 Years’: Cancer Centers Prepare for Daraxonrasib DemandMay 29th, 2026
- AACR: NCI Leader Letai Battles ‘Misinformation’ To Assure Anxious Researchers That ‘Funding Is Strong’April 22nd, 2026
Grant Support
- Changing the natural history of pancreatic ductal adenocarcinoma with cancer interception strategiesUNIVERSITY OF PENNSYLVANIA2026–2031
- Abramson Cancer Center Support GrantUNIVERSITY OF PENNSYLVANIA1997–2027
- Combined CD40 Activation And CTLA4 Blockade In MelanomaNational Cancer Institute2011–2012
- Immunoregulation And Immunotherapy Of Breast CancerNational Cancer Institute2005–2011
- Telomerase As A Widely Expressed Tumor AntigenNational Cancer Institute2001–2004
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
